Xeris Biopharma Holdings, Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureSep 9 →InsidersNo open-market buys. 8 insiders sold $2.9M, 15 of 19 sales on a 10b5-1 plan.→HoldersBlackRock 8.4%D. E. Shaw & 4.5%Vanguard 4.2%→Financing →PeersClosest companies: AXSM, PRAX, AMPH→
From the filings
Figures
- Revenue
- $335.4Mlast 12 months
- Net income
- −$17.2Mlast 12 months
- Operating cash flow
- $48.5Mlast 12 months
- Cash and equivalents
- $121.7Mat the last balance sheet
- Total debt
- $252.6Mat the last balance sheet
- Shares outstanding
- 173.6M shareson issue